MSCs isolated from patients with ischemic vascular disease have normal angiogenic potential

Molecular Therapy

Volumn 22, Issue 11, 2014, Pages 1888-1889

  Sanz Nogués, Clara ^a   O'Brien, Timothy ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD PRESSURE REGULATION; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CLINICAL EFFECTIVENESS; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; LIMB AMPUTATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NOTE; OUTCOME ASSESSMENT; RISK FACTOR; SMOKING; VASCULAR DISEASE; ANGIOGENESIS; ANIMAL; CYTOLOGY; ISCHEMIA; LEG; MESENCHYMAL STROMA CELL; PATHOLOGY; PROCEDURES;

ANIMALS; HUMANS; ISCHEMIA; LEG; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 84964313255     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.191     Document Type: Note

References (16)

1. Liew, A and O'Brien, T (2012). Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia. Stem Cell Res Ther 3: 28.
2. Heeschen, C (2004). Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109: 1615-1622.
3. Teraa, M, Sprengers, RW, Westerweel, PE, Gremmels, H, Goumans, M-JTH, Teerlink, T et al. (2013). Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients. PLoS ONE 8: e55592.
4. Gremmels, H, Teraa, M, Quax, PHA, den Ouden, K, Fledderus, JO and Verhaar, MC (2014). Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls. Mol Ther 22: 1960-1970.
5. Armstrong, DGD, Wrobel, JJ and Robbins, JMJ (2007). Are diabetes-related wounds and amputations worse than cancer? Int Wound J 4: 286-287.
6. Botti, C, Maione, C, Coppola, A, Sica, V and Cobellis, G (2012). Autologous bone marrow cell therapy for peripheral arterial disease. Stem Cells Cloning 5: 5-14.
7. Stolzing, A, Jones, E, McGonagle, D and Scutt, A (2008). Age-related changes in human bone marrow- derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 129: 163-173.
8. Lu, D, Chen, B, Liang, Z, Deng, W, Jiang, Y, Li, S et al. (2011). Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract 92: 26-36.
9. Lee, HC, An, SG, Lee, HW, Park, J-S, Cha, KS, Hong, TJ et al. (2011). Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J 76: 1750-1760.
10. Lasala, GP, Silva, JA, Gardner, PA and Minguell, JJ (2010). Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis. Angiology 61: 551-556.
11. Gupta, PK, Chullikana, A, Parakh, R, Desai, S, Das, A, Gottipamula, S et al. (2013). A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med 11: 143.
12. Caplan, AI (2009). Why are MSCs therapeutic? New data: new insight. J Pathol 217: 318-324.
13. Griffin, MD, Ritter, T and Mahon, BP (2010). Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 21: 1641-1655.
14. Griffin, MD, Ryan, AE, Alagesan, S, Lohan, P, Treacy, O and Ritter, T (2013). Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol 91: 40-51.
15. Rosen, AB, Kelly, DJ, Schuldt, AJ, Lu, J, Potapova, IA, Doronin, SV et al. (2007). Finding fluorescent needles in the cardiac haystack: Tracking human mesenchymal stem cells labeled with quantum dots for quantitative in vivo three-dimensional fluorescence analysis. Stem Cells 25: 2128-2138.
16. Huang, XP, Sun, Z, Miyagi, Y, McDonald Kinkaid, H, Zhang, L, Weisel, RD et al. (2010). Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 122: 2419-2429.